Infuse Hospital Administrators Promo

Safe and Effective

INFUSE® Bone Graft is recombinant human bone morphogenetic protein-2 applied to an absorbable collagen sponge carrier. One of the functions of the protein is to stimulate natural bone formation. Overall, bone morphogenetic protein technology has a lengthy history of extensive research and study dating back more than 50 years.

INFUSE® Bone Graft was cleared by the U.S. Food & Drug Administration in 2002 for use in Anterior Lumbar Interbody Fusion spine surgical procedures. Additional approvals were received in 2004 and 2007 for trauma and oral-maxillofacial (OMF) indications, respectively.

In 2008, INFUSE® Bone Graft received the coveted Prix Galien Award. The distinguished award recognizes those scientific technologies that have revolutionized their field and significantly impacted the practice of science and medicine. In 2015, Infuse Bone Graft/Medtronic Interbody Fusion Device was approved for:

  • Use in OLIF51™ Procedures with certain sizes of the PEEK Perimeter® Implant at a single level from L5-S1.
  • Use in OLIF25™ Procedures with certain sizes of the PEEK Clydesdale® Implant at a single level from L2-L5.
  • Use in anterior lumbar interbody fusion (ALIF) procedures with certain sizes of the PEEK Perimeter Implant at a single level from L2-S1.

The Infuse Bone Graft/Medtronic Interbody Fusion Device is indicated for spinal fusion procedures in skeletally mature patients for the treatment of degenerative disc disease (DDD) at one level from L2-S1 (the lower part of the back). DDD is defined as a disc that has deteriorated and causes back pain. The disc degeneration is confirmed by history and x-ray studies. Prior to this surgery, patients should have been non-responsive to at least six months on non-operative therapy.

Understand the advantages and benefits of using INFUSE® Bone Graft

Icon Alert Important Safety Information - Spine
Icon Alert Important Safety Information - Trauma
Icon Alert Important Safety Information - OMF